36 related articles for article (PubMed ID: 35471863)
1. Comparison of Treatment and Prognosis Between Follicular Variant Papillary Thyroid Carcinoma and Classical Papillary Thyroid Carcinoma.
Zhang B; Wu W; Liu J; Liang Z; Zong L
Horm Metab Res; 2023 Dec; 55(12):855-868. PubMed ID: 37813352
[TBL] [Abstract][Full Text] [Related]
2. Impact of radioiodine therapy on recurrence and survival outcomes in intermediate-risk papillary thyroid carcinoma -A systematic review and meta-analysis.
Chandekar KR; Satapathy S; Bal C
Clin Endocrinol (Oxf); 2024 Feb; 100(2):181-191. PubMed ID: 38050454
[TBL] [Abstract][Full Text] [Related]
3. American Thyroid Association Guidelines and National Trends in Management of Papillary Thyroid Carcinoma.
Gordon AJ; Dublin JC; Patel E; Papazian M; Chow MS; Persky MJ; Jacobson AS; Patel KN; Suh I; Morris LGT; Givi B
JAMA Otolaryngol Head Neck Surg; 2022 Dec; 148(12):1156-1163. PubMed ID: 36326739
[TBL] [Abstract][Full Text] [Related]
4. Radioactive iodine administration is not associated with improved disease-specific survival in classic papillary thyroid carcinoma greater than 4 cm confined to the thyroid.
Lee-Saxton YJ; Palacardo F; Greenberg JA; Egan CE; Marshall TE; Tumati A; Beninato T; Zarnegar R; Fahey TJ; Finnerty BM
Surgery; 2024 Jan; 175(1):215-220. PubMed ID: 38563429
[TBL] [Abstract][Full Text] [Related]
5. The clinical outcomes of COVID-19 infection in patients with a history of thyroid cancer: A nationwide study.
Sahin M; Haymana C; Demirci I; Tasci I; Rıfat E; Unluturk U; Satman I; Demir T; Cakal E; Ata N; Ertugrul D; Salman S; Sahin I; Dagdelen S; Celik O; Caglayan M; Atmaca A; Sonmez A
Clin Endocrinol (Oxf); 2021 Oct; 95(4):628-637. PubMed ID: 33872399
[TBL] [Abstract][Full Text] [Related]
6. Indicators of microbial-rich environments and the development of papillary thyroid cancer in the California Teachers Study.
Clarke CA; Reynolds P; Oakley-Girvan I; Lee E; Lu Y; Yang J; Moy LM; Bernstein L; Horn-Ross PL
Cancer Epidemiol; 2015 Aug; 39(4):548-53. PubMed ID: 26007306
[TBL] [Abstract][Full Text] [Related]
7. Radioactive iodine therapy improves overall survival outcome in oncocytic carcinoma of the thyroid by reducing death risks from noncancer causes: A competing risk analysis of 4641 patients.
Zhang K; Wang X; Wei T; Li Z; Zhu J; Chen YW
Head Neck; 2024 Apr; ():. PubMed ID: 38572629
[TBL] [Abstract][Full Text] [Related]
8. Incidentally Detected Metachronous Malignancy in Patients of Papillary Carcinoma of Thyroid Posthigh-Dose Radioiodine Therapy.
Mishra A; Singh V; Khandelwal Y; Smitha AM; Kavali DJP; Barai S
Indian J Nucl Med; 2023; 38(3):264-269. PubMed ID: 38046960
[TBL] [Abstract][Full Text] [Related]
9. Stage-Dependent Death Hazard and Conditional Survival of Patients with Papillary Thyroid Cancer.
Qu H; Zhang Z; Zhang D; Okamoto T; Zhang P; Zhang H; Dong W
Thyroid; 2023 Oct; 33(10):1264-1267. PubMed ID: 36974364
[No Abstract] [Full Text] [Related]
10. Modified dynamic risk stratification system further predicts individual outcome in patients with intermediate-risk papillary thyroid cancer.
Cuéllar DI; De Los Reyes A; Llamas-Olier A
Ann Endocrinol (Paris); 2023 Apr; 84(2):242-248. PubMed ID: 35483449
[TBL] [Abstract][Full Text] [Related]
11. A comparative analysis of treatment efficacy in intermediate-risk thyroid cancer.
Abiri A; Nguyen T; Goshtasbi K; Torabi SJ; Kuan EC; Armstrong WB; Tjoa T; Haidar YM
Eur Arch Otorhinolaryngol; 2023 May; 280(5):2525-2533. PubMed ID: 36651960
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012.
Carhill AA; Litofsky DR; Ross DS; Jonklaas J; Cooper DS; Brierley JD; Ladenson PW; Ain KB; Fein HG; Haugen BR; Magner J; Skarulis MC; Steward DL; Xing M; Maxon HR; Sherman SI
J Clin Endocrinol Metab; 2015 Sep; 100(9):3270-9. PubMed ID: 26171797
[TBL] [Abstract][Full Text] [Related]
13. TIMING OF RADIOACTIVE IODINE THERAPY DOES NOT IMPACT OVERALL SURVIVAL IN HIGH-RISK PAPILLARY THYROID CARCINOMA.
Suman P; Wang CH; Abadin SS; Block R; Raghavan V; Moo-Young TA; Prinz RA; Winchester DJ
Endocr Pract; 2016 Jul; 22(7):822-31. PubMed ID: 27018620
[TBL] [Abstract][Full Text] [Related]
14. Radioactive Iodine-Refractory Differentiated Thyroid Cancer in the Elderly.
Gosain R; Alexander JS; Gill A; Perez C
Curr Oncol Rep; 2018 Sep; 20(10):82. PubMed ID: 30206719
[TBL] [Abstract][Full Text] [Related]
15. Radiofrequency ablation for treatment of locally recurrent thyroid cancer presenting as a metastatic lymph node with dense macrocalcification: A case report and literature review.
Yoo RE; Kim JH; Paeng JC; Park YJ
Medicine (Baltimore); 2018 Mar; 97(9):e0003. PubMed ID: 29489641
[TBL] [Abstract][Full Text] [Related]
16. Outcomes and Trends of Treatments in High-Risk Differentiated Thyroid Cancer.
Abiri A; Goshtasbi K; Torabi SJ; Kuan EC; Armstrong WB; Tjoa T; Haidar YM
Otolaryngol Head Neck Surg; 2023 Apr; 168(4):745-753. PubMed ID: 35471863
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
